1 Michel RP, Langleben D, Dupuis J.The endothelin system in pulmonary hypertension[J].Can J Physiol Pharmacol, 2003;81: 542-54 2 Wort SJ, WoodM, Warner TD, Evans TW, Mitchell JA.Endogenously released endohtelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation[J].Am J Respir Cell Mol Biol, 2001;25:104-10 3 Sato K, Morio Y, Morris KG, Rodman DM, McMurtry IF. Mechanism of hypoxic pulmonary vasoconstriction involves ET (A) receptor-mediated inhibition of K(ATP) channel[J].Am J Physiol Lung CellMol Physiol, 2000;278:L434-42 4 Brayden JE.Functional roles of KATP channels in vascular smooth muscles[J].Clin Exp Pharmacol Physiol, 2002;29:312-6 5 Cole WC, Clement-Chomienne O.ATP-sensitive K+ channels of vascular smooth muscle cells[J].J Cardiovasc Electrophysiol, 2003;14:94-103 6 Wang H.Pharmacological characteristics of the novel antihypertensive drug, iptakalim hydrochloride and its molecular mechanisms[J].Drug Dev Res, 2003;58:65-8 7 Higenbottam TW, Laude EA.Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension[J]. Chest, 1998;114:72-8 8 Tilton RG, Munsch CL, Sherwood SJ, Chen YF, Wu C, et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist[J].Pulm Pharmacol Ther, 2000;13:87-97 9 Watanuki M, Horie M, Tsuchiya K, Obayashi K, Sasayama S. Endothelin-1 inhibition of cardiac ATP-sensitive K+ channels via pertussin-toxin-sensitive G-proteins[J].Cardiovasc Res, 1997; 33:123-30 10 Cui Y, Tran S, Tinker A, Clapp LH.The molecular composition of KATP channels in human pulmonary artery smooth muscle cells and their modulation by growth[J].Am J Respir CellMol Biol, 2002;26:135-43 11 Wanstall JC.The pulmonary vasodilator properties of potassium channel opening drugs[J].Gen Pharmacol, 1996;27:599-605 12 Mandegar M, Yuan JX.Role of K+ channels in pulmonary hypertension[J].Vascular Pharmacol, 2002;38:25-33 |